Abstract
LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have